Skip to main content
. Author manuscript; available in PMC: 2021 Mar 26.
Published in final edited form as: Am J Kidney Dis. 2020 May 15;76(2):299–302. doi: 10.1053/j.ajkd.2020.02.451

Figure 1.

Figure 1.

Clinical course of the 19 patients treated with ICIs for advanced malignancies while receiving dialysis, grouped by cancer type. Patients with arrows survived beyond 2 years or are still alive at last follow-up. Eight patients (42%) survived longer than 12 months or are still in remission.*Patient who had a failed kidney transplant. ❖Patient who received 2 additional cycles of Pembro after 24 months of Atezo. Abbreviations: Atezo, atezolizumab; Avel, avelumab; Ipi, ipilimumab; Nivo, nivolumab; Pembro, pembrolizumab.